Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

α-Lipoic Acid as Adjunctive Treatment for Schizophrenia: An Open-Label Trial.

Sanders LLO, de Souza Menezes CE, Chaves Filho AJM, de Almeida Viana G, Fechine FV, Rodrigues de Queiroz MG, Gonçalvez da Cruz Fonseca S, Mendes Vasconcelos SM, Amaral de Moraes ME, Gama CS, Seybolt S, de Moura Campos E, Macêdo D, Freitas de Lucena D.

J Clin Psychopharmacol. 2017 Dec;37(6):697-701. doi: 10.1097/JCP.0000000000000800.

PMID:
29053478
2.

Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study.

Kim NW, Song YM, Kim E, Cho HS, Cheon KA, Kim SJ, Park JY.

Int Clin Psychopharmacol. 2016 Sep;31(5):265-74. doi: 10.1097/YIC.0000000000000132.

PMID:
27276401
3.

Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms.

Vasconcelos GS, Ximenes NC, de Sousa CN, Oliveira Tde Q, Lima LL, de Lucena DF, Gama CS, Macêdo D, Vasconcelos SM.

Schizophr Res. 2015 Jul;165(2-3):163-70. doi: 10.1016/j.schres.2015.04.017. Epub 2015 Apr 30.

PMID:
25937462
4.

An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes.

Ratliff JC, Palmese LB, Reutenauer EL, Tek C.

Clin Schizophr Relat Psychoses. 2015 Jan;8(4):196-200. doi: 10.3371/CSRP.RAPA.030113.

PMID:
23471087
5.

Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.

Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.

CNS Drugs. 2013 Jan;27(1):57-65. doi: 10.1007/s40263-012-0022-1.

PMID:
23233269
6.

Antioxidant treatments for schizophrenia.

Magalhães PV, Dean O, Andreazza AC, Berk M, Kapczinski F.

Cochrane Database Syst Rev. 2016 Feb 5;2:CD008919. doi: 10.1002/14651858.CD008919.pub2. Review.

PMID:
26848926
7.

Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia.

Vidović B, Milovanović S, Dorđević B, Kotur-Stevuljević J, Stefanović A, Ivanišević J, Miljković M, Spasić S, Stojanović D, Pantović M.

Psychiatr Danub. 2014 Sep;26(3):205-13.

8.

A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia.

Kim E, Park DW, Choi SH, Kim JJ, Cho HS.

J Clin Psychopharmacol. 2008 Apr;28(2):138-46. doi: 10.1097/JCP.0b013e31816777f7.

PMID:
18344723
9.

Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study).

Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schütte K, Gries FA.

Diabetologia. 1995 Dec;38(12):1425-33.

PMID:
8786016
10.

Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.

Barnes TR, Leeson VC, Paton C, Costelloe C, Simon J, Kiss N, Osborn D, Killaspy H, Craig TK, Lewis S, Keown P, Ismail S, Crawford M, Baldwin D, Lewis G, Geddes J, Kumar M, Pathak R, Taylor S.

Health Technol Assess. 2016 Apr;20(29):1-46. doi: 10.3310/hta20290.

11.

Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia?

Seybolt SE.

Med Hypotheses. 2010 Dec;75(6):572-5. doi: 10.1016/j.mehy.2010.07.034. Epub 2010 Aug 12.

PMID:
20708342
12.

A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia.

Emsley R, Chiliza B, Asmal L, du Plessis S, Phahladira L, van Niekerk E, van Rensburg SJ, Harvey BH.

Schizophr Res. 2014 Sep;158(1-3):230-5. doi: 10.1016/j.schres.2014.06.004. Epub 2014 Jul 2.

PMID:
24996507
13.

Electroencephalographic study of chlorpromazine alone or combined with alpha-lipoic acid in a model of schizophrenia induced by ketamine in rats.

Sampaio LRL, Borges LTN, Barbosa TM, Matos NCB, Lima RF, Oliveira MN, Gularte VN, Patrocínio MCA, Macêdo D, Vale OCD, Vasconcelos SMM.

J Psychiatr Res. 2017 Mar;86:73-82. doi: 10.1016/j.jpsychires.2016.12.003. Epub 2016 Dec 3.

PMID:
27951451
14.

Effects of oral α-lipoic acid administration on body weight in overweight or obese subjects: a crossover randomized, double-blind, placebo-controlled trial.

Li N, Yan W, Hu X, Huang Y, Wang F, Zhang W, Wang Q, Wang X, Sun K.

Clin Endocrinol (Oxf). 2017 May;86(5):680-687. doi: 10.1111/cen.13303. Epub 2017 Feb 26.

PMID:
28239907
15.

Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial.

Kashani L, Shams N, Moazen-Zadeh E, Karkhaneh-Yousefi MA, Sadighi G, Khodaie-Ardakani MR, Rezaei F, Rahiminejad F, Akhondzadeh S.

J Psychiatr Res. 2017 Nov;94:70-77. doi: 10.1016/j.jpsychires.2017.06.011. Epub 2017 Jun 28.

PMID:
28688338
16.

Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial.

Lerner V, Miodownik C, Gibel A, Kovalyonok E, Shleifer T, Goodman AB, Ritsner MS.

Clin Neuropharmacol. 2008 Jan-Feb;31(1):25-33. doi: 10.1097/WNF.0b013e31806450da.

PMID:
18303488
17.

The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia.

Fan X, Song X, Zhao M, Jarskog LF, Natarajan R, Shukair N, Freudenreich O, Henderson DC, Goff DC.

Acta Psychiatr Scand. 2017 Nov;136(5):465-472. doi: 10.1111/acps.12799. Epub 2017 Aug 29.

PMID:
28851055
18.

Simvastatin adjunct therapy for negative symptoms of schizophrenia: a randomized double-blind placebo-controlled trial.

Tajik-Esmaeeli S, Moazen-Zadeh E, Abbasi N, Shariat SV, Rezaei F, Salehi B, Akhondzadeh S.

Int Clin Psychopharmacol. 2017 Mar;32(2):87-94. doi: 10.1097/YIC.0000000000000159.

PMID:
27941358
19.

Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.

Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, Watanabe K, Mimura M, Uchida H.

Schizophr Bull. 2013 Sep;39(5):993-8. doi: 10.1093/schbul/sbt090. Epub 2013 Jul 1.

20.

Alpha-lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reactivity and morphology of vessels already damaged by streptozotocin-diabetes.

Koçak G, Aktan F, Canbolat O, Ozoğul C, Elbeğ S, Yildizoglu-Ari N, Karasu C; ADIC Study Group--Antioxidants in Diabetes-Induced Complications.

Diabetes Nutr Metab. 2000 Dec;13(6):308-18.

PMID:
11232755

Supplemental Content

Support Center